+49 761-389 49-0
Measurable residual disease (MRD) monitoring has rapidly become a standard approach to risk stratification for acute lymphoblastic leukemia (ALL). MRD facilitates personalized precision oncology by accurate prediction of imminent relapse and early therapy intensification for high risk cases.
Dr. Rishu Agarwal is a highly accomplished molecular pathologist and Dr. Stephen Ma, a laboratory hematology advanced trainee with a special interest in molecular diagnostics, both practice at the Austin Hospital in Melbourne. They will present their experiences of implementing the LymphoTrack® MRD Solution for Acute Lymphoblastic Leukemia (ALL) research. They will share their insight on the advantages and limitations of using NGS for measuring MRD, and compare MRD monitoring data generated by NGS and flow cytometry.
Speakers:
Rishu Agarwal
MBBS PhD FRCPA Molecular Haematologist Austin Health & Peter MacCallum Cancer Center Melbourne, Australia
Stephen B. Ma
BbiomedSc BSc(Hon) MD DipMus LMusA(dist) Laboratory Haematology Registrar Austin Health Melbourne, Australia
